Company Profile

Medicon, Inc's compounds are synthesized de novo or, more often, are known agents chemically modified to enhance their pharmacological properties, with particular emphasis on their efficacy and safety. Modification of the widely used nonsteroidal anti-inflammatory drug (NSAID) sulindac has led to two compounds, OXT-328 and OXT-922. Compared to conventional sulindac, both display superior efficacy and safety, as shown in preclinical models. Key to these properties is the type of their chemical modification and the resultant novel mechanism of action, clearly distinct from that of sulindac. Extensive preclinical studies with OXT-328 demonstrated its ability to both prevent (>90%) and treat colon cancer. These studies also indicated a highly favorable safety profile. Medicon’s pipeline includes a number of similarly modified NSAIDs and other compounds. The firm's studies to date indicate a platform technology with the interesting feature that compounds display individual properties that give them specificity of target cancer. Cancers effectively treated with our compounds in preclinical tumor models include some of the most lethal human cancers, such as colon cancer, pancreatic cancer, lung cancer and breast cancer, including the dreaded triple-negative subtype. In terms of anti-inflammatory properties, three NSAID derivatives show excellent efficacy in animal models of inflammation and markedly reduced gastrointestinal toxicity